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Abstract 
 
The engineering of responsive multifunctional delivery systems that combine therapeutic 
and diagnostic (theranostic) capabilities holds great promise and interest. We describe the 
design of thermosensitive liposome-nanoparticle (NP) hybrids that can modulate drug 
release in response to external heating stimulus. These hybrid systems were successfully 
engineered by the incorporation of gold, silver, and iron oxide NPs into the lipid bilayer of 
lysolipid-containing thermosensitive liposomes (LTSL). Structural characterization of LTSL-NP 
hybrids using cryo-EM and AFM revealed the incorporation of metallic NPs into the lipid 
membranes without compromising doxorubicin loading and retention capability. The 
presence of metallic NPs in the lipid bilayer reinforced bilayer retention and offered a 
nanoparticle concentration-dependent modulation of drug release in response to external 
heating. In conclusion, LTSL-NP hybrids represent a promising versatile platform based on 
LTSL liposomes that could further utilize the properties of the embedded NPs for 
multifunctional theranostic applications. 
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1. Introduction 
 
Liposomes are self-assembled phospholipid vesicles that have been clinically approved as a 
nanoscale delivery system for various therapeutic applications (Allen and Cullis, 2013 and 
Barenholz, 2012). Liposomes can effectively entrap both hydrophilic (Lozano et al., 2015 and 
Li et al., 1998) and hydrophobic compounds (Chen et al., 2010, Koudelka and Turánek, 2012 
and Lozano et al., 2015) in their aqueous core or the lipid bilayer, respectively. Liposomes 
are biocompatible, biodegradable and can effectively modify the pharmacokinetic profile of 
their loaded drugs (Sawant and Torchilin, 2012). Stealth liposomes can passively accumulate 
at the tumor site as they leak through malformed blood vessels while avoiding healthy 
tissues and organs (Gabizon et al., 1994 and Gabizon and Martin, 1997). Next-generation 
liposomes that can trigger-release their drug content in response to external stimuli have 
been developed to improve drug bioavailability and overall therapeutic efficacy (Al-Ahmady 
et al., 2014 and Al-Ahmady et al., 2015). The most clinically advanced such vesicle system is 
commercially known as ThermoDox®, a lysolipid-containing temperature-responsive 
liposome (LTSL) that is currently in clinical trials for treatment of solid tumors in 
combination with mild hyperthermia (HT) (Al-Ahmady and Kostarelos, 2016). 
 
Over the last few years, advances in nanotechnology have dramatically increased interest in 
developing metallic nanoparticles (NPs) for a wide range of applications (Grzelczak and Liz-
Marzan, 2013, Hormeno et al., 2014, Johannsen et al., 2010, Liu et al., 2012, Maestro et al., 
2014, Visaria et al., 2006 and Wong and Liu, 2010). The nanoscale size of metallic NPs such 
as gold (AuNPs), silver (AgNPs), superparamagnetic iron oxides (SPIO) and their novel optical 
and magnetic properties enable their use for both imaging and therapeutic purposes. For 
example, the enhanced surface plasmon resonance of AuNPs makes them particularly 
attractive for imaging and photo-thermal applications (Maestro et al., 2014). The absorption 
of light at certain wavelengths causes the oscillation of surface electrons and subsequent 
local heat generation, that can be controlled by the intensity of the laser beam irradiation, 
duration of NP exposure and the concentration of AuNPs (Alkilany et al., 2012). 
 
Similarly, SPIO NPs have been used extensively as a contrast agent for magnetic resonance 
imaging (MRI). The magnetic properties of SPIO NPs can also be exploited for the generation 
of magnetically-mediated hyperthermia (Chanda et al., 2010). The exposure of SPIO NPs to 
an alternating magnetic field can generate high local heating by Neel fluctuations which 
have showed potential in cancer therapy (Jordan et al., 2006 and Maier-Hauff et al., 2007). 
NP-induced hyperthermia has the potential to overcome some of the limitations of 
conventional heating techniques when treating deep or non-accessible tumors (Preiss and 
Bothun, 2011). However, the inherent hydrophobic surface character of metallic NPs and 
their limited colloidal stability can significantly affect their biological performance. 
 
We and others have previously shown the possibility of using liposome technology as a 
delivery platform that could allow the incorporation of metallic NPs (Al-Jamal et al., 2008, 
Jain et al., 2003 and Lozano et al., 2012). Liposomal incorporation of metallic NPs has proved 
to be an effective way to increase nanoparticle stability and biocompatibility in biological 
conditions (Lozano et al., 2012 and Preiss and Bothun, 2011). This can be achieved by either 
the incorporation of hydrophobic NPs within the lipid membrane or encapsulation of the 
hydrophilic NPs in the liposomal aqueous core (Tai et al., 2009). Alternatively, metallic NPs 
can be functionalized onto the liposomal surface by either physical or chemical conjugation 
(Chithrani et al., 2010 and Pornpattananangkul et al., 2010). To date several examples of 
liposome-NP hybrids have been designed for diagnostic (Soga et al., 2010), or simply for 
colloidal stabilization (Kojima et al., 2008 and Lozano et al., 2012) purposes, with some 
interesting examples of smart hybrid systems that can trigger release in response to 
external stimuli. Such cases of thermosensitive liposome-NP hybrids were designed to utilize 
the photonic and electromagnetic properties of NPs for local heat generation and triggered 
content release (Paasonen et al., 2010, Tai et al., 2009 and Wu, 2008). As a proof of concept, 
several studies have demonstrated the release of encapsulated dye molecules from such 
hybrid systems (Bealle et al., 2012, Chen et al., 2010 and Paasonen et al., 2010). However, 
only a few studies have reported the potential of combining thermosensitive liposome-NP 
hybrids with therapeutic agents for combinatory therapeutic and diagnostic applications 
(Tian et al., 2011). 
 
The aim of the present work was to engineer and characterize doxorubicin loaded-
thermosensitive, liposome-NP hybrids as multimodal smart systems to control drug release. 
Drug (doxorubicin) loaded, LTSL were chosen for this study as the most advanced TSL that 
are currently in clinical trials (Clesion.com, 2016 and Landon et al., 2011). The incorporation 
of three different types of metallic NPs into LTSL was studied and the capacity of the hybrid 
systems to modulate drug release was investigated. 
 
2. Materials and methods 
2.1. Materials 
 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine (MSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were kind gifts from Lipoid GmbH 
(Ludwigshafen, Germany). Ammonium sulfate, sodium hydroxide, chloroform and methanol 
were purchased from Fisher Scientific. 1,6-Diphenyl-l,3,5-hexatriene (DPH) was purchased 
from Invitrogen. Diethyl ether, doxorubicin hydrochloride (DOX), 4-(2-hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES), sodium chloride (NaCl), Sephadex® G-50, oleic 
acid-functionalized magnetic SPIO NPs solution 5 mg/ml in toluene, octanethiol-
functionalized AuNPs 2% solution in toluene, decanethiol-functionalized AgNPs 0.1% (w/v) 
in hexane, 8-anilino-1-naphthalenesulfonic acid (ANS), and tetrahydrofuran were purchased 
from Sigma. 
 
2.2. Preparation and characterization of liposomes and liposome-NP hybrids 
 
Lysolipid containing temperature-sensitive liposomes (LTSL) composed of DPPC:MSPC:DSPE-
PEG2000 86:10:4 (molar ratio) were prepared using the reverse phase evaporation method 
[RP] and the lipid film-reverse phase evaporation method [F-RP] (Fig. 1A). For the RP 
method the lipids dissolved in chloroform/methanol mixture were mixed in 25 ml round 
bottom flask and then 6 ml of chloroform/diethylether (1:1, v/v) and 1.5 ml of 240 mM 
ammonium sulfate buffer (pH 5.4) were added at 1:4 v/v (aqueous/organic). In order to 
form w/o emulsion, the mixture was sonicated for 15 min in a bath sonicator at 40 °C. 
Organic solvents were then evaporated using rotary evaporator (BÜCHI, Switzerland) at 460 
mbar and 40 °C for 2 h resulting in the formation of a gel-like phase followed by aqueous 
phase formation. Large unilamellar liposomes (LUVs) formed by this process were then 
reduced in size by 30 min sonication at 60 °C using a bath sonicator. 
 
 
 
 
Fig. 1.  
(A) Schematic of the protocols used for LTSL preparation: reverse phase evaporation [RP] and film-reverse phase 
evaporation [F-RP]. (B) Colloidal stability summary and doxorubicin encapsulation efficiency (EE%) of the LTSL prepared by 
[RP] and [F-RP]. Data obtained by Nanosizer ZS and fluorescence spectrophotometer. (C) Effect of LTSL preparation 
protocol: fluorescence anisotropy values of (i) DPH and (ii) ANS and% doxorubicin released at (iii) 37 °C and (iv) 42 °C using 
the [RP] (squares and solid lines) and [F-RP] (circles and dashed lines) protocols. 
To prepare the liposomes by F-RP method, the same procedure described above was 
applied with the exception that a lipid film was first prepared by evaporating 
chloroform:methanol from the lipid mixture. This then followed by re-dissolving the lipid 
film in the chloroform/diethylether/ammonium sulfate mixture as described earlier. 
 
For the preparation of liposome-NP hybrids, F-RP method was applied. First, the exact 
amount of hydrophobic NPs dispersion (5 μg or 10 μg) was added to 25 ml round bottom 
flask. The organic solvent in which the NPs were dispersed was removed using rotary 
evaporator at 6 mbar and 40 °C for 1 h. The lipids mixture of DPPC:MSPC:DSPE-PEG2000 
86:10:4 (molar ratio) dissolved in chloroform/methanol (4:1) were then added and the 
organic solvents were evaporated to form the lipid film containing the NPs. The resulting 
lipid film was then re-dissolved the lipid film in 6 ml of chloroform/diethylether (1:1). 
Following this step 1.5 ml of 240 mM ammonium sulfate buffer (pH5.4) was added and the 
mixture was sonicated for 15 min in a bath sonicator at 40 °C. Organic solvents were then 
evaporated using rotary evaporator at 460 mbar and 40 °C for 2 h and the size of LUVs of 
LTSL-Np hybrids was then reduced by bath sonication as described earlier. 
 
Liposome size and surface charge were measured by using Zetasizer Nano ZS (Malvern, 
Instruments, UK). For size measurement samples were diluted with HEPES buffer saline 
(HBS) composed of 20 mM HEPES, 150 mM NaCl, pH 7.4 and measured in 1 ml cuvettes. 
Zeta potential was measured in disposable Zetasizer cuvettes and sample dilution was 
performed with distilled water. 
 
2.3. Cryo-electron microscopy (Cryo-EM) 
 
Visualization of samples with Cryo-EM was performed to study the morphology of LTSL-NPs 
hybrids and to confirm the incorporation of metallic NPs. Sample preparation was carried 
out in a temperature- and humidity-controlled chamber using a fully automated (PC-
controlled) vitrification robot (Vitrobot). 46 A specimen grid was dipped into a suspension 
and withdrawn, and excess liquid was blotted away. Thin films were formed between the 
bars of the grids. To vitrify these thin films, the grid was shot into melting ethane. The grids 
with vitrified thin films were analyzed in a CM-12 transmission microscope (Philips, 
Eindhoven, The Netherlands) at 170 °C using a Gatan-626 cryo-specimen holder and 
cryotransfer system (Gatan, Warrendale, PA). The vitrified films were studied at 120 kV and 
at standard low-dose conditions. 
 
2.4. Atomic force microscopy (AFM) 
 
Sample analysis with AFM was then performed to study the effect of NPs incorporation on 
the bilayer thickness. 20 μl of liposome dispersion in a concentration of 5 mM was 
deposited on the surface of a newly cleaved mica sheet (Agar Scientific, Essex, UK) and was 
allowed to adsorb for 1 min. Unbound liposomes were washed out by filtered distilled water 
and then dried by dust-free compress air. Images were taken in tapping-mode using a 
Multimode AFM, E-type scanner, Nanoscope IV controller with Nanoscope 5.31r1 control 
software (Bruker Surface Nano, Cambridge, UK). The tip was a silicon tapping tip with 10 nm 
curvature radius (NSG01, NTI-Eutope, Apdldoorn, The Netherlands). Typical resonant 
frequency of the tapping-mode silicon cantilever of 150 kHz with a force constant of 5.5 
N/m was used. A scan rate of 1 Hz was used to scan a 5 μm2 of the mica surface with a 
resolution of 512 × 512 pixels. WSxM 5.0 software was used to process, filter and flatten the 
images. 
 
2.5. Differential scanning calorimetry (DSC) 
 
Phase transition temperature (Tt), of LTSL Liposomes and the three types of LTSL-NP hybrids 
were studied with DSC. This method is use to study the change in bilayer structure from 
solid gel-phase into liquid crystalline-phase as the temperature increased. Liposomes were 
prepared as LUVs by F-RP method. Samples were first prepared at the concentration of 15 
mM and then concentrated 5 times by centrifugation at 13,000 rpm for 30 min using 0.22 
μm Spin-X Centrifuge Tube Filters (Sigma-Aldrich, UK). 20 μl of the concentrated liposome 
dispersion were then transferred and sealed into the hermetic Tzero™ DSC pan and 
analyzed by Q2000 DSC (TA Instruments, USA) at 1 °C per min from 30 °C to 60 °C. 
 
2.6. Fluorescence anisotropy measurements 
 
Fluorescence anisotropy experiments were performed to study the effect of metallic NPs 
incorporation on the liposomes membrane fluidity. A hydrophobic probe (DPH) and 
hydrophilic probe (ANS) were used to monitor the changes in the bilayer fluidity at the 
hydrophobic region of the lipid membrane and near the liposomes surface, respectively. 
Experiments were performed as previously described (Al-Ahmady et al., 2012). Briefly, 
liposomes were further diluted to 0.025 mM and divided into two 4 ml aliquots. DPH 
solution in tetrahydrofuran (0.8 mM, 2.5 μl) or an aqueous ANS solution (10 mM, 4 μl) was 
mixed with the liposomes at 500:1 lipid/DPH or 25:1 lipid/ANS. To allow the probes to be 
incorporated, the samples were shaken at room temperature for 2 h and then left overnight 
before starting measurements. Fluorescence polarization was then measured by a LS–50 B 
spectrofluorometer (Perkin Elmer) equipped with automated polarizer and thermostatic cell 
holder connected to a water bath to control the sample temperature. For the DPH 
experiment, the anisotropy measurements were carried out at an excitation wavelength of 
395 nm (slit of 10 nm) and emission wavelength of 476 nm (slit of 5 nm). Measurements 
were started at 25 °C, and then the temperature was increased gradually up to 60 °C. 
Boltzmann curve fitting of the experimental values were performed using Origin software. 
The samples were equilibrated for at least 6 min after each temperature change. 
Fluorescence anisotropy was then measured automatically by the spectrofluorometer based 
on Eq. (1); 
 
 
 
where r is the fluorescence anisotropy and IVV and IVH are the emission intensity excited 
with vertically polarized light and measured with emission polarizer oriented in a parallel or 
perpendicular direction to the plane of excitation, respectively. G is an instrument specific 
factor calculated to correct the instrument polarization, which is equal to IHV/IHH, and 
obtained by measuring the vertically and horizontally polarized emission intensities after 
excitation with horizontally polarized light. 
 
2.7. Doxorubicin loading using pH-gradient method 
 
Remote doxorubicin loading into pre-formed liposomes was performed using pH gradient 
method. Ammonium sulfate buffer 240 mM (pH 5.4) was used for the liposomes 
preparation as mentioned earlier then external buffer exchange was performed by gel 
filtration through Sephadex® G-50 column equilibrated with HBS (pH 7.4). Doxorubicin 
hydrochloride (5 mg/ml) was added to the liposome suspensions at 20:1 lipid/doxorubicin 
mass ratio (i.e. 0.187 mg of doxorubicin for 5 mM liposomes). This was then followed by 2 h 
incubation at 37 °C. 
 
After incubation liposomes were passed again through Sephadex® G-50 column to remove 
any free doxorubicin. Encapsulation efficiency (% EE) was calculated by comparing the total 
fluorescence intensity of doxorubicin post and pre gel filtration, diluted to the same final 
lipid concentration using Eq. (2); 
 
% EE = I(t) post column/I(t) pre column *100 
 
where, I(t) is the total fluorescence intensity of the liposome suspension after adding 2 μl 
Triton X-100 (10% in HBS, pH 7.4). 
 
2.8. Doxorubicin release studies 
 
Doxorubicin release was measured by taking advantage of the fluorescence quenching 
process. When doxorubicin is encapsulated inside the liposomes, its concentrations is very 
high resulting in self-quenching of the fluorescence signal. When the ambient temperature 
exceeded the liposome Tt, doxorubicin was released from the liposomes and its 
concentration is diluted resulting in increase in fluorescence intensity, which is used to 
monitor the release process. 
 
Doxorubicin release studies were performed in HBS. Samples were incubated at 37 °C and 
42 °C with a shaking water bath (Grant, U.K.). 20 μl Samples were then measured at 
different time points at 480/595 nm excitation and emission wavelengths (slit 15/20 nm) 
using PerkinElmer Luminescence Fluorimeter (LS50B). The intensity of the fluorescence 
signals was then normalized and the% of doxorubicin release was calculated using Eq. (3); 
 
% Release = [I(s) − I(0)]/[I(t) − I(0)] * 100 
 
Where, I(s) is the fluorescence intensity of individual samples at different time points, I(0) is 
the background fluorescence intensity of liposome samples after purification and I(t) is the 
fluorescence intensity of liposomes suspension after the addition of 2 μl of 10% Triton X-100 
in HBS (pH 7.4). 
 
3. Results 
3.1. Engineering thermosensitive liposome-NPs hybrids 
 
Thermosensitive liposome-NP hybrids were engineered using the reverse phase evaporation 
method (Szoka and Papahadjopoulos, 1978) based on the hypothesis that significantly 
higher NP incorporation within the lipid bilayer would be afforded. To test this, two 
alternative reverse phase evaporation-based protocols were compared, namely, the original 
reverse phase evaporation [RP] and the modified lipid film hydration-reverse phase 
evaporation [F-RP], aiming to maintain the thermal sensitivity of the lysolipid-containing 
LTSL (Fig. 1A). 
 
First, plain LTSL liposomes were prepared by both RP and F-RP that did not show a 
significant difference in mean vesicle diameter and surface properties (Fig. 1B). However, 
fluorescence anisotropy studies and a doxorubicin release experiment indicated significant 
differences between the two protocols. Fluorescence anisotropy studies were performed 
using two different types of membrane-bound probes (DPH and ANS) to allow monitoring of 
the molecular interactions at the alkyl chain and head group regions of the vesicle bilayer, 
respectively. Higher anisotropy values were observed from LTSL liposomes prepared with 
the RP protocol, indicating an increase in bilayer rigidity compared to the F-RP protocol (Fig. 
1Ci, ii). This was also associated with a reduction in the temperature-responsiveness of the 
LTSL-RP illustrated by the limited doxorubicin release after 60 min of exposure to mild HT 
(42 °C). In comparison, LTSL liposomes prepared with F-RP protocol preserved their thermo-
responsiveness evidenced by complete drug content release (>90% release) at 42 °C (Fig. 
1Civ). 
 
Based on the above and in order to preserve the thermal sensitivity of LTSL liposomes, the 
F-RP protocol was chosen for the engineering of the LTSL-NP hybrid vesicles. 
Thermosensitive liposome-NP hybrids were designed to incorporate the metallic NPs within 
the phospholipids bilayer. Three different types of metallic NPs were studied: AuNPs, AgNPs 
and SPIO NPs. In order to ensure that the NPs were embedded in the lipid bilayer, 
hydrophobic NPs with a size that is comparable to, or smaller than the thickness of a lipid 
membrane (<5 nm) were selected (Fig. 2A) (Al-Jamal et al., 2008). 
 
 
Fig. 2.  
(A) Hydrophobic NPs characteristics. (B) Cryo-EM micrographs showing the morphology and incorporation of metallic NPs 
in the lipid bilayer of the liposomes as indicated by the arrows, and (C) AFM (amplitude and 3D images and cross-section 
analysis) for 5 mM LTSL without and with 10 μg/ml of AuNPs, AgNPs and SPIO NPs. 
 
3.2. Cryo-EM and AFM imaging of thermosensitive liposome-NP hybrids 
 
The incorporation of all three types of metallic NP into LTSL vesicle bilayers by the F-RP 
method was performed and the morphological characterization of the ensuing hybrid 
systems was studied by cryo-EM and AFM. Although the exact quantification of metallic NPs 
embedded in the liposomes was not quantified, we have studied the interaction between 
metallic NP within the LTSL vesicles using cryo-EM and AFM imaging. LTSL-NPs hybrids 
imaged by cryo-EM, indicated that the incorporation of the NP into the lipid bilayer was 
taking place (Fig. 2B, see arrows). Surface topology of LTSL-NP hybrids was also studied with 
AFM. Interestingly, AFM cross-section analysis (Fig. 2C) suggested that metallic NP 
incorporation into LTSL increased the height (i.e. thickness) of the lipid bilayer from 6 to 8 
nm to almost 18–20 nm. This was in agreement with previously reported studies from other 
liposome hybrid systems (Tian et al., 2011). Overall, the microscopy evidence obtained by 
cryo-EM and AFM corroborated to suggest that the metallic NPs were localized within the 
lipid bilayers. 
 
3.3. The effect of NP concentration on hybrid system properties 
 
To study the effect of the incorporated NP concentration on the properties of LTSL hybrid 
systems, AuNP were chosen as it is considered the most popular NP for efficient light 
induced heating and attracted great attention in the past for their multifunctional character. 
Two different concentrations of AuNPs were selected for these studies; 5 and 10 μg/ml. 
Incorporation of AuNP at both concentrations resulted in hybrid systems less than 100 nm in 
mean diameter, low polydispersity index (PDI) and a slightly negative surface charge (Fig. 
3A). Fluorescence anisotropy studies showed higher r values for the LTSL-AuNP hybrids 
(compared to LTSL alone) indicating an increase in bilayer rigidity by the incorporation of 
AuNPs (Fig. 3Bi, ii). LTSL-AuNP hybrids were successfully loaded with the anticancer drug 
doxorubicin and maintained good stability at body temperature as evidenced by drug 
retention at 37 °C (Fig. 3Ciii). Interestingly, a concentration-dependent modulation of 
doxorubicin release at mild HT (42 °C) was observed by the incorporation of AuNP within the 
LTSL bilayers (Fig. 3Civ), that could be expected as a result of the anisotropy-determined 
increase in bilayer rigidity. 
 
 
Fig. 3.  
(A) Colloidal stability summary and doxorubicin encapsulation efficiency (EE%) of LTSL and LTSL-AuNP hybrids. Data 
obtained by Nanosizer ZS and fluorescence spectrophotometer. (B) Fluorescence anisotropy of (i) DPH and (ii) ANS and% 
doxorubicin released at (iii) 37 °C and (iv) 42 °C for 5 mM LTSL (squares and solid lines) and LTSL embedded with 5 (circles 
and dashed lines) and 10 (up-triangles and dotted lines) μg/ml of AuNPs. 
 
3.4. The effect of metal NP type on hybrid system properties 
 
The effect of NP type on the hybrid vesicle characteristics and temperature-triggered 
release properties was investigated next. Three different types of metallic NPs were 
compared by allowing their incorporation into LTSL lipid bilayers at 10 μg/ml using the F-RP 
protocol. Physicochemical characterization of LTSL-AuNP/AgNP/SPIO hybrid systems 
revealed that all LTSL-NP hybrids resulted in mean vesicle diameter (and PDI) comparable to 
LTSL alone (Fig. 4A). It is also worth noting that the bilayer Tt after incorporation of the 
three different metallic NPs remained consistent with that of the LTSL alone (between 40.5–
41 °C). The three types of LTSL-NP hybrid vesicles were found to be more surface charge 
neutral than their plain LTSL liposome counterpart. Interestingly, all LTSL-NP hybrid systems 
were able to be remote-loaded with doxorubicin at a higher encapsulation efficiency 
compared to LTSL liposomes prepared by F-RP. The encapsulation efficiency of all tested 
were almost comparable to what observed from LTSL-RP. The presence of NPs in the lipid 
bilayer of LTSL liposomes prepared by F-RP method may offer better preservation of the pH 
gradient required for doxorubicin loading process. This could be due to the increase in 
bilayer rigidity in the presence of NPs compared to plain LTSL. As observed from florescence 
anisotropy studies. This again indicated that the incorporation of metallic NPs into LTSL lipid 
bilayers resulted in a higher bilayer rigidity revealed by an increase in r values (Fig. 4Bi, ii), 
which was almost comparable to r values observed before from LTSL-RP (Fig. 1Ci). This 
increase in bilayer rigidity was observed both in the core and head group region of the 
phospholipid membrane irrespective to the type of the NPs incorporated, even though it did 
not lead to a change in the overall Tt of the bilayer as noted above. In terms of doxorubicin 
release profile, similar to LTSL-AuNP hybrids described above, LTSL-AgNP and LTSL-SPIO 
hybrids maintained good drug retention at body temperature ( Fig. 4Biii), while offering 
controlled drug release for 60 min under mild HT conditions (Fig. 4Biv). All three types of 
LTSL-NP hybrids released doxorubicin at significantly lower rates compared to the LTSL 
liposomes. Overall, no significant differences were observed in both physicochemical and 
drug release characteristics among the three different types of LTSL-NP hybrids, in contrast 
to the sharp differences in comparison to LTSL liposomes alone. 
 
 
Fig. 4.  
(A) Colloidal stability summary and doxorubicin encapsulation efficiency (EE%) of LTSL and LTSLNP hybrids. Data obtained 
by Nanosizer ZS and fluorescence spectrophotometer. (B) Fluorescence anisotropy of (i) DPH and (ii) ANS and 1 h% 
doxorubicin released at (iii) 37 °C and (iv) 42 °C for 5 mM LTSL (squares and solid lines) and LTSL embedded with 10 μg/ml 
of AuNPs (circles), AgNPs (up-triangles), and SPIO NPs (down-triangles). 
 
4. Discussion 
Even though liposomes and metallic NPs are independently already in clinical practice, the 
combination of liposome-NP hybrids is still an exploratory approach to design a new 
generation of multifunctional delivery systems (Preiss and Bothun, 2011). The aim of such 
hybrid systems is to combine the capabilities of both liposomes and NPs and therefore 
provide an advanced platform for theranostic applications. Thermosensitive liposome-NP 
hybrid systems are interesting examples of such design strategies as they aim to take 
advantage of the thermal properties of NPs in order to achieve remote drug release 
(Pradhan et al., 2010 and Volodkin et al., 2009). Several examples of thermosensitive 
liposome-NP hybrids have been proposed recently by incorporating NPs either in the 
aqueous core, lipid membrane or by surface adsorption. From these three different designs, 
membrane-embedded and surface-adsorbed NPs showed the highest content release. This 
effect was studied in detail by Passonen et al. by incorporating 2–4 nm AuNPs into 
DPPC:DSPC TSL to report the percentage of calcein release after 5–10 min of continuous 
exposure to UV light at 250 nm (Paasonen et al., 2007). Maximum release was achieved 
from membrane embedded Au-C6SH NPs and surface adsorbed DPPE-NanoAu® NPs. 
Similarly, the extent of carboxyfluorescein dye release from DPPC liposomes decorated with 
hollow Au nanoshells (Wu, 2008) and DPPC:DPTAP:CHOL-AuNPs complexes (Volodkin et al., 
2009) was highly dependent on the proximity of the NPs to the lipid bilayer. The reason 
behind that was possibly due to a more efficient and localized direct heat transport from the 
NPs to the liposomal bilayer compared to the encapsulated AuNPs (Paasonen et al., 2007). 
These results also suggested that the mechanism behind the observed triggered release 
could be due to the formation of transient pores in the bilayer or due to other forms of 
mechanical disruption of the lipid bilayer by the incorporated NPs. Fluorescence anisotropy 
has also been widely used to study the effect of NPs incorporation on lipid membrane 
packing and fluidity, showing that this is largely dependent on the concentration, size, 
position of NPs incorporated and the temperature tested (Park et al., 2005, Park et al., 2006 
and Park et al., 2009). 
 
In agreement with our findings, incorporation of small hydrophobic NPs (<5 nm) decreased 
the lipid membrane fluidity (membrane rigidifying effect) particularly at temperatures 
below the phase transition temperature of the lipid membrane (Park et al., 2005, Park et al., 
2006 and Park et al., 2009). Membrane rigidity was augmented with increasing the NP 
concentration. The most likely explanation for such effects is the small size of NPs (smaller 
than the thickness of bilayer) that allows for complete NP incorporation within the lipid 
bilayer (Park et al., 2005, Park et al., 2006 and Park et al., 2009). Increased bilayer rigidity 
can also explain the different rates of drug release observed from the three types of 
liposome-NP hybrids we studied here. This observation also agreed with a previous report 
by Chen et al. who showed that the release of an encapsulated dye molecule (5,6-
Carboxyfluorescein) from DPPC liposomes was reduced by increasing the amount of SPIO 
NPs embedded within the lipid membrane (Chen et al., 2010). Interestingly, that study also 
showed that content leakage was enhanced when triggered by an external magnetic field, 
further suggesting the critical role played by the incorporated NPs (Chen et al., 2010). The 
opposite effect on lipid membrane rigidity was observed when the incorporated NPs were 
near or just exceeding the thickness of the lipid membrane. Increases in DPPC membrane 
fluidity and a decreased vesicle phase transition temperature were reported by the 
incorporation of AgNPs larger than 5 nm (Bothun, 2008). The distortion of the lipid bilayer to 
accommodate the NPs was suggested as responsible for the decrease in lipid ordering and 
increased membrane fluidity (Bothun, 2008). No significant effect on bilayer fluidity was 
reported from NPs encapsulated in the aqueous core (Bothun, 2008 and Preiss and Bothun, 
2011). 
 
Despite previous reports of interesting new designs of thermosensitive liposome-NP 
hybrids, only a few studies have investigated the therapeutic relevance of these systems by 
the encapsulation of clinically-used drug molecules. These examples involved the co-
encapsulation of both therapeutic drug molecules, such as doxorubicin (Pradhan et al., 
2010) or methotrexate (Zhu et al., 2009), and metallic NPs in the liposomal aqueous 
compartment and showed interesting effects in response to external stimuli (Pradhan et al., 
2010 and Zhu et al., 2009). 
 
The capability of combining therapeutic and imaging functionalities in a single liposome-NP 
hybrid system can provide an attractive theranostic approach for many diseases in which 
both diagnosis and therapy need to be combined. Such hybrid systems can be imaged to 
offer non-invasive assessment blood kinetics and tissue distribution, targeted at specific 
cells and tissue, as well as offer controlled drug release at the target site on external 
stimulation. Consequently, this would provide the potential to have better prediction of the 
therapeutic activity and open new insights into more personalized medications. In the 
present study, we reported thermosensitive liposome-NP hybrid systems by incorporating 
different types of metallic NPs in the bilayer of clinically-developed LTSL formulations. 
Altering the concentration and the type of the NPs we can effectively control drug release 
from LTSL liposomes without interference with drug loading and drug retention. LTSL-NP 
hybrid systems present a potential multifunctional vector of great modular capacity, whose 
properties can be modulated by the type of NPs incorporated within the lipid bilayer. 
 
More research is warranted to optimize the choice of TSL formulation and biocompatibility 
of the liposome-NP hybrids. In addition, the structural integrity of the liposome-NP hybrids 
in vivo needs to be further investigated to address the possibility of NP release from 
liposomes during blood circulation and the consequences this could have on drug retention, 
drug pharmacology and long term safety profile. Furthermore, the therapeutic and imaging 
potential of liposome-NP hybrids needs to be further explored using clinically relevant non-
invasive external triggering techniques. 
 
5. Conclusions 
In conclusion, we present the engineering of doxorubicin-loaded thermosensitive liposome-
NPs hybrids as potential theranostic platforms. The use of metallic NPs with mean diameters 
smaller than the thickness of lipid membrane ensured successful incorporation within the 
vesicle lipid bilayer as evidenced with cryo-EM and AFM studies. As a result of that an 
increase in bilayer rigidity and tunable doxorubicin release profile from the hybrid systems 
was obtained after heating. Our data suggested that this approach can provide an 
alternative strategy to design stable liposome-NP hybrids with additional functionalities that 
are contributed by the type of metallic NPs incorporated. We suggest that LTSL-NP hybrids 
may offer multifunctional delivery systems with the potential to achieve simultaneous 
tracking and triggered-release. 
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